BIO Deutschland calls for the clinical development of Covid-19 therapies

Press release

The supplementary budget for 2020 has earmarked about €9.4 billion for measures to combat the effects of the coronavirus pandemic. The government has already set aside more than €1 billion for coronavirus vaccine research and has made a large portion of these funds available to three vaccine developers in Germany. However, it has not yet considered providing support for the later stages of clinical development for promising drugs against Covid-19. In an open letter to the Federal Minister of Research as well as to the Federal Ministers of Health and Economic Affairs, BIO Deutschland has called for such late-stage funding to be initiated quickly in order to enable in particular severely ill patients to receive effective coronavirus therapies.

The full text of the press release as well as the open letter (in German) can be found here:
www.biodeutschland.org/de/pressemitteilungen/biotechnologieverband-fordert-foerderung-der-klinischen-entwicklung-von-covid-19-therapien.html?year=2020